关于 "Aurora Kinase" 的结果53+ 个结果
- CD532 hydrochloride
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction
- LY3295668 (AK-01)CAS: 1919888-06-4
LY3295668 (AK-01) is a potent, orally active and specific inhibitor of Aurora A kinase with Ki of 0.8 nM and 1038 nM for AURKA and AURKB, respectively.
- ChiauranibCAS: 1256349-48-0
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
- Aurkin ACAS: 1534060-58-6
Aurkin A是极光A激酶（Aurora A Kinase，也称Aurka）与TPX2相互作用的变抗抑制剂，通过靶向TPX2结合位点，Kd为3.77 μM。
- SNS-314CAS: 1057249-41-8
SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.
- MLN8237 (Alisertib)CAS: 1028486-01-2
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂，通常用于治疗实体瘤和血液系统恶性肿瘤。
- VX-680 (MK-0457,Tozasertib)CAS: 639089-54-6
VX-680 (MK-0457,Tozasertib)是一种有效的Aurora激酶抑制剂，对Aurora A/B/C的K i 值分别为0.6、18、4.6nM，具有抗癌活性。
- PF-03814735CAS: 942487-16-3
PF-03814735 是一种有效的、具有口服生物利用度的 Aurora1 和 Aurora2 激酶的可逆抑制剂，IC50 值分别为 0.8nM 和 5nM 。
- TAS-119CAS: 1453099-83-6
TAS-119 是一种有效的，选择性的，具有口服活性的 Aurora A 抑制剂，IC50 为 1.0 nM。TAS-119 对 Aurora A 的选择性高于其他蛋白激酶，包括 Aurora B (IC50 为 95 nM)。TAS-119 具有有效的抗肿瘤活性。
- ENMD-2076 L-(+)-Tartaric acidCAS: 1291074-87-7
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂，对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。
| 货号 | 产品名称 | CAS号 | 靶点 / 通路 | 引用 | 结构 |
|---|---|---|---|---|---|
| GC91148 | JAK Inhibitor 31 | 2891469-99-9 | JAK | ||
一种JAK2抑制剂 | |||||
| GC10442 | MK-8745 | 885325-71-3 | Other Apoptosis | ||
An Aurora A kinase inhibitor | |||||
| GC14409 | ZM 447439 | 331771-20-1 | Other Apoptosis | ||
Selective inhibitor of Aurora B kinase | |||||
| GC42933 | Binucleine 2 | 220088-42-6 | Cytoskeleton & Motor Proteins | ||
An inhibitor of Drosophila Aurora B kinase | |||||
| GC62189 | CD532 hydrochloride | - | Aurora Kinase | ||
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction | |||||
| GC48982 | CD532 | 1639009-81-6 | G2/S | ||
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction | |||||
| GC12208 | MLN8054 | 869363-13-3 | Aurora Kinase | ||
An inhibitor of Aurora A kinase | |||||
| GC10008 | GSK1070916 | 942918-07-2 | Other Apoptosis | ||
A potent inhibitor of Aurora B and C kinases | |||||
| GC33057 | LY3295668 (AK-01) | 1919888-06-4 | Aurora Kinase | ||
LY3295668 (AK-01) is a potent, orally active and specific inhibitor of Aurora A kinase with Ki of 0.8 nM and 1038 nM for AURKA and AURKB, respectively. | |||||
| GC17196 | Hesperadin | 422513-13-1 | Parasite | ||
Hesperadin是一种竞争性ATP结合抑制剂，对Aurora B激酶的IC50为250nM。 | |||||
| GC62145 | Chiauranib | 1256349-48-0 | c-FMS | ||
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy. | |||||
| GC72964 | Aurkin A | 1534060-58-6 | Aurora Kinase | ||
Aurkin A是极光A激酶（Aurora A Kinase，也称Aurka）与TPX2相互作用的变抗抑制剂，通过靶向TPX2结合位点，Kd为3.77 μM。 | |||||
| GC48971 | AZD 1152 (hydrochloride) | 722543-50-2 | Aurora Kinase | ||
A prodrug for a potent Aurora B inhibitor | |||||
| GC25940 | SNS-314 | 1057249-41-8 | Aurora Kinase | ||
SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1. | |||||
| GC12690 | MLN8237 (Alisertib) | 1028486-01-2 | Other Apoptosis | ||
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂，通常用于治疗实体瘤和血液系统恶性肿瘤。 | |||||
| GC11549 | VX-680 (MK-0457,Tozasertib) | 639089-54-6 | Autophagy | ||
VX-680 (MK-0457,Tozasertib)是一种有效的Aurora激酶抑制剂，对Aurora A/B/C的Ki值分别为0.6、18、4.6nM，具有抗癌活性。 | |||||
| GC14651 | Reversine | 656820-32-5 | Autophagy | ||
Reversine是一种靶向Aurora A激酶、Aurora B激酶和MPS1（Monopolar Spindle 1）激酶的非特异性、具有口服活性的小分子抑制剂。Reversine常用于细胞分化和多种癌症的研究。 | |||||
| GC17284 | Anacardic acid | 16611-84-0 | Epigenetic Reader Domain | ||
A histone acetyltransferase inhibitor | |||||
| GC14592 | KW 2449 | 1000669-72-6 | Aurora Kinase | ||
A multi-kinase inhibitor | |||||
| GC18074 | PF-03814735 | 942487-16-3 | VEGFR | ||
PF-03814735 是一种有效的、具有口服生物利用度的 Aurora1 和 Aurora2 激酶的可逆抑制剂，IC50 值分别为 0.8nM 和 5nM 。 | |||||
| GC62482 | TAS-119 | 1453099-83-6 | Aurora Kinase | ||
TAS-119 是一种有效的，选择性的，具有口服活性的 Aurora A 抑制剂，IC50 为 1.0 nM。TAS-119 对 Aurora A 的选择性高于其他蛋白激酶，包括 Aurora B (IC50 为 95 nM)。TAS-119 具有有效的抗肿瘤活性。 | |||||
| GC10638 | AT9283 | 896466-04-9 | Autophagy | ||
A broad spectrum kinase inhibitor | |||||
| GC12145 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | PDGFR | ||
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂，对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。 | |||||
| GC50050 | Hesperadin hydrochloride | - | Aurora Kinase | ||
A multi-kinase inhibitor | |||||